Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eyenovia Inc (EYEN)

Eyenovia Inc (EYEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,000
  • Shares Outstanding, K 16,442
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,250 K
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate -0.31
  • Low Estimate -0.55
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.60 +42.69%
on 11/13/19
4.39 -15.49%
on 12/02/19
+0.90 (+32.03%)
since 11/05/19
3-Month
2.60 +42.69%
on 11/13/19
5.06 -26.67%
on 09/19/19
+0.46 (+14.15%)
since 09/05/19
52-Week
2.40 +54.58%
on 12/21/18
6.98 -46.87%
on 04/16/19
-0.31 (-7.71%)
since 12/04/18

Most Recent Stories

More News
Eyenovia, Inc. (EYEN) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).

EYEN : 3.71 (+4.80%)
All You Need to Know About Eyenovia, Inc. (EYEN) Rating Upgrade to Strong Buy

Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

EYEN : 3.71 (+4.80%)
Companies Strive to Tackle Ocular Diseases as Rates of Incidences Grow

There is an alarming increase in the frequency of eye-related diseases, particularly in developed countries, which in turn is expected to drive the growth of the global retinal drugs market. There are...

OPHT : 1.39 (-0.71%)
AMBS : 0.0175 (-1.13%)
AGTC : 2.98 (-1.32%)
ISEE : 4.30 (+5.13%)
EYEN : 3.71 (+4.80%)
IRIX : 2.39 (+3.46%)
Eyenovia Reports Third Quarter 2019 Financial Results

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced...

EYEN : 3.71 (+4.80%)
Can European Buyouts Aid Canopy Growth's (CGC) Q2 Earnings?

Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.

MRUS : 16.65 (-1.94%)
EYEN : 3.71 (+4.80%)
PRVL : 14.03 (-2.50%)
CGC : 18.60 (+1.20%)
What's in Store for Applied Materials' (AMAT) Q4 Earnings?

Applied Materials' (AMAT) technology leadership position and strong product line in Display and Services are likely to reflect on fiscal fourth-quarter results.

MOMO : 37.17 (+2.14%)
AMAT : 55.84 (-0.45%)
PDD : 36.58 (+2.04%)
EYEN : 3.71 (+4.80%)
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q2 Earnings?

A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.

MRUS : 16.65 (-1.94%)
EYEN : 3.71 (+4.80%)
CGC : 18.60 (+1.20%)
PRVL : 14.03 (-2.50%)
Overstock (OSTK) to Report Q3 Earnings: What's in Store?

Overstock's (OSTK) third-quarter results are likely to reflect strength across retail and blockchain businesses.

OSTK : 7.26 (-3.84%)
MOMO : 37.17 (+2.14%)
PDD : 36.58 (+2.04%)
EYEN : 3.71 (+4.80%)
5 Biotech Stocks Set to Beat Q3 Earnings Estimates

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

ASND : 109.79 (-5.55%)
SAGE : 60.18 (-59.67%)
NGM : 16.58 (-1.19%)
EYEN : 3.71 (+4.80%)
ACIU : 8.19 (+5.81%)
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?

Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress, when it reports Q3 results.

FOLD : 10.02 (-6.79%)
CGC : 18.60 (+1.20%)
EYEN : 3.71 (+4.80%)
CRON : 6.65 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade EYEN with:

Business Summary

Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc....

See More

Key Turning Points

2nd Resistance Point 4.03
1st Resistance Point 3.87
Last Price 3.71
1st Support Level 3.53
2nd Support Level 3.34

See More

52-Week High 6.98
Fibonacci 61.8% 5.23
Fibonacci 50% 4.69
Fibonacci 38.2% 4.15
Last Price 3.71
52-Week Low 2.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar